International Journal of Endocrinology and Metabolism

Published by: Kowsar

Safety of Raloxifene in Hemodialysis Patients

Didy Jacobsen 1 , *
Author Information
1 Geriatric Department, Radboud University Medical Center, Nijmegen, The Netherlands
Article information
  • International Journal of Endocrinology and Metabolism: September 01, 2012, 10 (4); 638-639
  • Published Online: September 29, 2012
  • Article Type: Letter
  • Received: May 9, 2012
  • Revised: May 9, 2012
  • Accepted: May 12, 2012
  • DOI: 10.5812/ijem.6285

To Cite: Jacobsen D. Safety of Raloxifene in Hemodialysis Patients, Int J Endocrinol Metab. 2012 ; 10(4):638-639. doi: 10.5812/ijem.6285.

Copyright © 2012, Research Institute For Endocrine Sciences and Iran Endocrine Society. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
  • 1. Saito O, Saito T, Asakura S, Akimoto T, Inoue M, Ando Y, et al. Effects of Raloxifene on Bone Metabolism in Hemodialysis Patients With Type 2 Diabetes. Int J Endocrinol Metab. 2012; 10(2): 464-9[DOI]
  • 2. Amerling R, Harbord NB, Pullman J, Feinfeld DA. Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series. Blood Purif. 2010; 29(3): 293-9[DOI][PubMed]
  • 3. Tanaka M, Itoh K, Matsushita K, Moriishi M, Kawanishi H, Fukagawa M. Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis. Ther Apher Dial. 2011; 15: 62-6[DOI][PubMed]
  • 4. Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, et al. KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD–mineral and bone disorder (CKD-MBD). Am J Kid Dis. 2010; 55(5): 773-99[DOI][PubMed]
  • 5. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int. 1996; 49(5): 1428-34[DOI][PubMed]
  • 6. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000; 35(4 Suppl 1)-31[DOI]
  • 7. Churchill DN, Taylor DW, Cook RJ, LaPlante P, Barre P, Cartier P, et al. Canadian Hemodialysis Morbidity Study. Am J Kidney Dis. 1992; 19(3): 214-34[PubMed]
  • 8. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974; 290(13): 697-701[DOI][PubMed]
  • 9. Rostand SG, Kirk KA, Rutsky EA. Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. Kidney Int. 1982; 22(3): 304-8[DOI][PubMed]
  • 10. Barrett-Connor E, Cox DA, Song J, Mitlak B, Mosca L, Grady D. Raloxifene and risk for stroke based on the framingham stroke risk score. Am J Med. 2009; 122(8): 754-61[DOI][PubMed]
  • 11. Kagan A, Dawber TR, Kannel WB, Revotskie N. The Framingham study: a prospective study of coronary heart disease. Fed Proc. 1962; 21(4): 52-7[PubMed]
  • 12. Kannel WB. Coronary heart disease risk factors in the elderly. Am J Geriatr Cardiol. 2002; 11(2): 101-7[DOI][PubMed]
  • 13. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J. Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. Ann Intern Med. 1961; 55: 33-50[PubMed]
  • 14. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991; 83(1): 356-62[DOI][PubMed]
  • 15. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol. 2002; 13(7): 1918-27[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments